Array and Biogen to collaborate

Array BioPharma (ARRY) and Biogen Idec (BIIB) sign a collaboration agreement for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders that were discovered through ARRY's Kinase-Directed Phenotypic Screening Platform. Under the terms of the agreement, BIIB will be responsible for all aspects of clinical development and commercialization and will fund research for three years. ARRY will be eligible for certain development and commercial milestone payments and royalties on top-line sales.

From other sites
Comments (3)
  • fafatooey
    , contributor
    Comments (435) | Send Message
    Crappy deal for ARRY
    28 May 2014, 09:53 AM Reply Like
  • duhaus
    , contributor
    Comments (320) | Send Message
    Well so far it doesn't seem to be too bad for it's stock price, early in the day yes but being up 5%+ is a good start.
    28 May 2014, 10:26 AM Reply Like
  • chicagomary
    , contributor
    Comments (448) | Send Message
    If the bigger bio's didn't give milestone payments a lot of the smaller biotechs couldn't survive. It is also helpful to ARRY to have their concepts verified. also,sometimes these deals lead to buyouts.
    28 May 2014, 09:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs